Genprex (GNPX) Liabilities and Shareholders Equity (2016 - 2026)

Genprex's Liabilities and Shareholders Equity history runs 11 years deep, the most recent figure standing at $20.3 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 237.89% year-over-year to $20.3 million; the TTM figure through Mar 2026 stood at $37.9 million (up 83.35% YoY), while the FY2025 annual figure was $10.2 million, up 146.32% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $20.3 million, up from $10.2 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $39.4 million in Q1 2022, with the low at $3.6 million in Q3 2025.
• The 5-year median for Liabilities and Shareholders Equity is $12.6 million (2024), against an average of $15.7 million.
• The sharpest annual moves came in 2024 and 2026: Liabilities and Shareholders Equity sank 76.52% in 2024, then surged 237.89% in 2026.
• Genprex's Liabilities and Shareholders Equity stood at $25.1 million in 2022, then slumped by 57.46% to $10.7 million in 2023, then tumbled by 61.35% to $4.1 million in 2024, then jumped by 146.32% to $10.2 million in 2025, then soared by 99.88% to $20.3 million in 2026.
• Business Quant data shows GNPX's Liabilities and Shareholders Equity at $20.3 million in Q1 2026, $10.2 million in Q4 2025, and $3.6 million in Q3 2025.